semaglutide bone mineral density GLP-1s may increase risk of osteoporosis and gout, new research finds GLP-1 Agonists and Orthopedic Surgery:

Countries within the EU evaluate semaglutide individually through their national medicines agencies, resulting in fragmented access compared to the unified FDA approval model in the United States

[ref] Endothelial cell injury is directly linked to atherosclerosis

If you're unable to maintain adequate fluid intake, or experience vomiting or diarrhoea that doesn't improve within 24 hours, contact your healthcare provider

Can a C-section shelf get worse over time

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet

The trial involves the administration of a drug or placebo to a cohort of approximately 118 participants, with the projected start and end dates in May 2023 and November 2024, respectively